Cargando…

Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review

WHAT IS KNOWN AND OBJECTIVE: Bevacizumab (BVZ) is an angiogenesis inhibitor that often works well with chemotherapeutic drugs for the treatment of solid intracranial tumours in children. This meta‐analysis discusses the efficacy and side effects of BVZ combined with irinotecan in the treatment of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Li, Qiang, Ma, Hai‐Yang, Sun, Tao, Xiang, Ruo‐Lan, Di, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689821/
https://www.ncbi.nlm.nih.gov/pubmed/32598559
http://dx.doi.org/10.1111/jcpt.13228
_version_ 1783613938144903168
author Xu, Yan
Li, Qiang
Ma, Hai‐Yang
Sun, Tao
Xiang, Ruo‐Lan
Di, Fei
author_facet Xu, Yan
Li, Qiang
Ma, Hai‐Yang
Sun, Tao
Xiang, Ruo‐Lan
Di, Fei
author_sort Xu, Yan
collection PubMed
description WHAT IS KNOWN AND OBJECTIVE: Bevacizumab (BVZ) is an angiogenesis inhibitor that often works well with chemotherapeutic drugs for the treatment of solid intracranial tumours in children. This meta‐analysis discusses the efficacy and side effects of BVZ combined with irinotecan in the treatment of patients (younger than 21 years of age) with recurrent, progressive or refractory intracranial tumours. METHODS: We searched for articles published before 31 October 2018 in PubMed, EMBASE, Cochrane library and Web of Science. We selected relevant literature on the combination of BVZ and irinotecan in the treatment of children with intracranial tumours. Objective response was evaluated by combining partial response (PR), complete response (CR), stable disease (SD) and progressive disease (PD), and survival time was evaluated by combining overall survival (OS) and progression‐free survival (PFS); common side effects were also analysed. All data included were obtained from single‐arm data, with no control groups. RESULTS AND DISCUSSION: A total of 13 studies involving 272 patients were included. We found that out of 41% patients who showed an objective response following the BVZ therapy combined with irinotecan, 28% achieved a PR, 13% achieved a CR, 32% showed a SD, and 43% had a PD; PFS and OS were 6.47 and 11.9 months, respectively; gastrointestinal dysfunction, leukopenia and hypertension were the three most common adverse events, accounting for 36.7%, 33.6% and 22.1%, respectively, whereas musculoskeletal disorders had the lowest occurrence, accounting for 3.9%. WHAT IS NEW AND CONCLUSION: BVZ combined with irinotecan‐based chemotherapy had a better response and prolonged survival in the treatment of paediatric intracranial tumours than radiation therapy or chemotherapy. Gastrointestinal dysfunction, leukopenia and hypertension were the toxic side effects with the highest incidence.
format Online
Article
Text
id pubmed-7689821
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76898212020-12-05 Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review Xu, Yan Li, Qiang Ma, Hai‐Yang Sun, Tao Xiang, Ruo‐Lan Di, Fei J Clin Pharm Ther Original Articles WHAT IS KNOWN AND OBJECTIVE: Bevacizumab (BVZ) is an angiogenesis inhibitor that often works well with chemotherapeutic drugs for the treatment of solid intracranial tumours in children. This meta‐analysis discusses the efficacy and side effects of BVZ combined with irinotecan in the treatment of patients (younger than 21 years of age) with recurrent, progressive or refractory intracranial tumours. METHODS: We searched for articles published before 31 October 2018 in PubMed, EMBASE, Cochrane library and Web of Science. We selected relevant literature on the combination of BVZ and irinotecan in the treatment of children with intracranial tumours. Objective response was evaluated by combining partial response (PR), complete response (CR), stable disease (SD) and progressive disease (PD), and survival time was evaluated by combining overall survival (OS) and progression‐free survival (PFS); common side effects were also analysed. All data included were obtained from single‐arm data, with no control groups. RESULTS AND DISCUSSION: A total of 13 studies involving 272 patients were included. We found that out of 41% patients who showed an objective response following the BVZ therapy combined with irinotecan, 28% achieved a PR, 13% achieved a CR, 32% showed a SD, and 43% had a PD; PFS and OS were 6.47 and 11.9 months, respectively; gastrointestinal dysfunction, leukopenia and hypertension were the three most common adverse events, accounting for 36.7%, 33.6% and 22.1%, respectively, whereas musculoskeletal disorders had the lowest occurrence, accounting for 3.9%. WHAT IS NEW AND CONCLUSION: BVZ combined with irinotecan‐based chemotherapy had a better response and prolonged survival in the treatment of paediatric intracranial tumours than radiation therapy or chemotherapy. Gastrointestinal dysfunction, leukopenia and hypertension were the toxic side effects with the highest incidence. John Wiley and Sons Inc. 2020-06-29 2020-12 /pmc/articles/PMC7689821/ /pubmed/32598559 http://dx.doi.org/10.1111/jcpt.13228 Text en © 2020 The Authors. Journal of Clinical Pharmacy and Therapeutics published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Xu, Yan
Li, Qiang
Ma, Hai‐Yang
Sun, Tao
Xiang, Ruo‐Lan
Di, Fei
Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
title Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
title_full Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
title_fullStr Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
title_full_unstemmed Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
title_short Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
title_sort therapeutic effect and side effects of bevacizumab combined with irinotecan in the treatment of paediatric intracranial tumours: meta‐analysis and systematic review
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689821/
https://www.ncbi.nlm.nih.gov/pubmed/32598559
http://dx.doi.org/10.1111/jcpt.13228
work_keys_str_mv AT xuyan therapeuticeffectandsideeffectsofbevacizumabcombinedwithirinotecaninthetreatmentofpaediatricintracranialtumoursmetaanalysisandsystematicreview
AT liqiang therapeuticeffectandsideeffectsofbevacizumabcombinedwithirinotecaninthetreatmentofpaediatricintracranialtumoursmetaanalysisandsystematicreview
AT mahaiyang therapeuticeffectandsideeffectsofbevacizumabcombinedwithirinotecaninthetreatmentofpaediatricintracranialtumoursmetaanalysisandsystematicreview
AT suntao therapeuticeffectandsideeffectsofbevacizumabcombinedwithirinotecaninthetreatmentofpaediatricintracranialtumoursmetaanalysisandsystematicreview
AT xiangruolan therapeuticeffectandsideeffectsofbevacizumabcombinedwithirinotecaninthetreatmentofpaediatricintracranialtumoursmetaanalysisandsystematicreview
AT difei therapeuticeffectandsideeffectsofbevacizumabcombinedwithirinotecaninthetreatmentofpaediatricintracranialtumoursmetaanalysisandsystematicreview